Dr Kate Fife - Publications

Individualised Predictions of the Survival Benefit Due to Adjuvant Therapy in a Randomised Trial of Sorafenib after Nephrectomy for Localised Renal Cell Carcinoma

25 Dec 2020

British Association of Dermatologists guidelines for the management of people with cutaneous squamous cell carcinoma 2020

04 Nov 2020

Selection of Oncogenic Mutant Clones in Normal Human Skin Varies with Body Site

21 Oct 2020

Combined Radiotherapy and New Systemic Therapies - Have We Moved Beyond Palliation?

27 Aug 2020

Treatment patterns and health outcomes in metastatic renal cell carcinoma patients treated with targeted systemic therapies in the UK

17 Jul 2020

Rembielak A, Sykes AJ, Fife K, Challapalli A, Nobes JP. Radiotherapy and Systemic Treatment for Non-melanoma Skin Cancer in the COVID-19 Pandemic. Clin Oncol (R Coll Radiol). 2020 Jul;32(7):417-419. doi: 10.1016/j.clon.2020.04.014. Epub 2020 May 7. PMID: 32418675; PMCID: PMC7203060.

07 May 2020

Fife K. Hedgehog pathway inhibitors come of age. Br J Dermatol. 2020 Jun;182(6):1322-1323. doi: 10.1111/bjd.18737. Epub 2019 Dec 17. PMID: 31849041.

17 Dec 2019

Buckley HL, Collinson FJ, Ainsworth G, Poad H, Flanagan L, Katona E, Howard HC, Murden G, Banks RE, Brown J, Velikova G, Waddell T, Fife K, Nathan PD, Larkin J, Powles T, Brown SR, Vasudev NS. PRISM protocol: a randomised phase II trial of nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinoma. BMC Cancer. 2019 Nov 14;19(1):1102. doi: 10.1186/s12885-019-6273-1. PMID: 31727024; PMCID: PMC6854710.

14 Nov 2019